Business Context and Reporting Period
This Form 8-K Current Report was filed by TRxADE HEALTH, INC. (trading symbol: MEDS) on October 4, 2022, with the earliest event reported on the same date. The filing details a private placement transaction and related agreements entered into to raise capital for general corporate purposes.
Key Financial Metrics and Transaction Details
The Company executed a securities purchase agreement with an institutional investor, resulting in the following capital raise metrics:
- Gross Proceeds: Approximately $1.75 million.
- Net Proceeds: Approximately $1.5 million (after deducting placement agent fees and estimated expenses).
- Securities Issued:
- 920,000 shares of Common Stock at $1.15 per share.
- Pre-Funded Warrants to purchase up to 601,740 shares at $1.14999 per warrant.
- Private Warrants to purchase up to 2,662,045 shares at an exercise price of $1.50 per share.
- Placement Agent Fees: 7.0% of gross proceeds from Shares and Pre-Funded Warrants, plus expense reimbursement up to $35,000.
The filing does not provide specific revenue, profit, cash flow, margin, or debt figures for the reporting period, as this document focuses solely on the capital raise event.
Material Changes and Agreements
The primary material change is the entry into a Material Definitive Agreement (Item 1.01) and the unregistered sale of equity securities (Item 3.02). Key terms include:
- Warrant Terms: Private Warrants include full ratchet anti-dilutive rights for 15 months and a minimum exercise price of $0.232. They require stockholder approval before exercise.
- Ownership Limits: Beneficial ownership is capped at 4.99%, extendable to 9.99% with notice. The Purchaser elected the 9.99% limit initially.
- Lock-Up Agreements: Officers and directors agreed not to sell securities for 90 days following the closing date (October 7, 2022).
- Registration Rights: The Company must file a Form S-1 within 60 days to register the resale of shares underlying the Private Warrants.
Outlook, Risks, and Contingencies
Management intends to use net proceeds for general corporate purposes. The transaction is subject to several contingencies and risks:
- Stockholder Approval: A special meeting or written consent must be held no later than December 20, 2022, to approve the issuance of shares upon exercise of Private Warrants. If not obtained initially, meetings must be held every six months thereafter.
- Issuance Restrictions: The Company is restricted from issuing Common Stock for 90 days after the later of Stockholder Approval or the Effective Date of the registration statement, and from entering variable rate transactions for nine months.
- Right of Participation: The Purchaser has a 12-month right to participate in up to 25% of subsequent equity or debt offerings.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks that could cause actual results to differ from projections, referencing risk factors in the Company's 10-K and 10-Q filings.
Investor Verification Checklist
- Verify the status of the required Stockholder Approval meeting scheduled by December 20, 2022.
- Confirm the effective date of the Form S-1 registration statement for the Private Warrants.
- Review the Company's latest 10-K and 10-Q filings for current liquidity, debt levels, and operating cash flow to assess the impact of the $1.5 million net proceeds.
- Monitor for any subsequent equity or debt offerings within the 12-month participation window.
- Check for any dilution events triggered by the full ratchet anti-dilutive provisions in the Private Warrants.